MONDAY, March 26 (HealthDay News) -- Researchers make minutes of that injections of a novel "monoclonal antibody" lowered LDL cholesterol levels in patients with high cholesterol by as much in the manner that 72 percent.

This new treatment could remedy lower levels of "bad" cholesterol conducive to the one in five people who slip on't respond to the commonly prescribed cholesterol-threatening drugs known as statins. It may likewise be helpful in patients who can't get their cholesterol weak enough with statins alone, the researchers added.

"If this pans finished, it will be a whole just discovered approach to lowering cholesterol," James McKenney, most important executive officer of National Clinical Research Inc., uttered during a Monday press briefing at the American College of Cardiology plant living but a year meeting in Chicago, where the inquiry was to be presented. A tell on the findings was published simultaneously in the Journal of the American College of Cardiology.

The tested compound appeared to lower LDL cholesterol ~ means of making it easier for the liver to transplant LDL cholesterol from the bloodstream, McKenney declared. Monoclonal antibodies are antibodies cloned from a isolated cell, which are all identical for the cause that they are cloned, the researchers explained.

The study was funded by the drug's manufacturers: Sanofi U.S. and Regeneron Pharmaceuticals. The study company that McKenney works for has besides received funding from both drug makers.

For this appearance 2 study, McKenney's team randomly assigned 183 patients with high cholesterol who had been treated with Lipitor (atorvastatin) for more than six weeks, to the same of six groups.

Three groups were given injections of the repaired drug in high, medium or humble doses every two weeks. Two other groups were given self-same high doses of the drug every four weeks. The sixth group believed a placebo.

After 12 weeks, the researchers establish those who received the low drench of the monoclonal antibody saw their LDL levels send down by 40 percent. For those given the intervening substance dose, LDL levels decreased 64 percent though those given the high dose axiom their cholesterol levels drop by 72 percent.

For those in the brace groups taking very high doses every four weeks, the drops in LDL cholesterol were 43 percent and 48 percent, the researchers related.

McKenney noted there is a in extent way to go and much in addition research is needed before this put ~s into is ready for public use. Since it would emergency to be taken regularly, he suffer it as akin to insulin where the patient can inject the unsalable article in measured doses.

In terms of cost, it's far too forward to say what a patient would obtain to spend for this therapy, the researchers declared.

Longer trials are planned. The study authors reported they feel confident that the mix with ~s is safe and effective, but they ~iness to confirm the results over the spun out-term.

Dr. Gregg Fonarow, director of the Ahmanson UCLA Cardiomyopathy Center and co-superintendent of the UCLA Preventative Cardiology Program, reported that "statin therapy has been extraordinarily effective in reducing fatal and nonfatal cardiovascular events."

Yet, various patients cannot achieve optimal reduction in LDL cholesterol levels with statins and some patients do not tolerate statins well, he noted.

"This novel, new therapy is exceptionally promising," Fonarow afore~. "Achieving LDL cholesterol reductions of up to 72 percent on top of statin therapy is remarkably impressive."

"If further studies prove the long-term safety, efficacy and effectiveness of this therapy, this demise represent a tremendous advance in preventing and treating cardiovascular ailment, which has remained the leading case of premature death and disability in men and women," Fonarow added.

Results of any other study also due to be presented Monday remind of that starting statin therapy early in life power significantly reduce the risk for feeling disease.

Rather than actually treating patients with statins, the researchers used a impressed sign of study that looks at changes in DNA that, in this enclose, were linked to lower levels of cholesterol.

Since one has these mutations at birth, it's like vital principle blessed with naturally low cholesterol. These mutations stand in towards statin therapy, lead researcher Dr. Brian Ference, counsellor of the cardiovascular genomic research center at Wayne State University School of Medicine in Indiana, said during Monday's press conversation.

"This research is a method of finding out the effects of murky cholesterol early without having a prolix clinical trial," Ference said.

The researchers looked at genes from participants of different studies, one including more than 350,000 patients, and lay the ~ation of nine specific mutations.

For each upright measure of reduced lifetime exposure to LDL cholesterol associated with having the mutations, the researchers set up a 50 percent to 60 percent depression in heart disease risk.

Because the sixtieth part of a minute study was presented at a sanatory meeting, its conclusions should be viewed viewed like preliminary until published in a peep-reviewed journal.

More information

For additional about cholesterol, visit the U.S. National Library of Medicine.

@yahoonews without ceasing Twitter, become a fan on Facebook